CH642682A5 - Peptide substance obtained from a trematode and its use as a medicinal product - Google Patents

Peptide substance obtained from a trematode and its use as a medicinal product Download PDF

Info

Publication number
CH642682A5
CH642682A5 CH82579A CH82579A CH642682A5 CH 642682 A5 CH642682 A5 CH 642682A5 CH 82579 A CH82579 A CH 82579A CH 82579 A CH82579 A CH 82579A CH 642682 A5 CH642682 A5 CH 642682A5
Authority
CH
Switzerland
Prior art keywords
cells
serotonin
degranulation
dialysate
mast
Prior art date
Application number
CH82579A
Other languages
English (en)
French (fr)
Inventor
Andre Capron
Christiane Mazingue
Daniel Camus
Jean-Paul Dessaint
Original Assignee
D Immunologie Et De Biolog Par
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D Immunologie Et De Biolog Par filed Critical D Immunologie Et De Biolog Par
Priority to CH82579A priority Critical patent/CH642682A5/fr
Priority to FR8001694A priority patent/FR2447194A1/fr
Publication of CH642682A5 publication Critical patent/CH642682A5/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CH82579A 1979-01-26 1979-01-26 Peptide substance obtained from a trematode and its use as a medicinal product CH642682A5 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CH82579A CH642682A5 (en) 1979-01-26 1979-01-26 Peptide substance obtained from a trematode and its use as a medicinal product
FR8001694A FR2447194A1 (fr) 1979-01-26 1980-01-25 Peptide extrait des cultures d'un trematode, son procede d'obtention et son emploi comme medicament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH82579A CH642682A5 (en) 1979-01-26 1979-01-26 Peptide substance obtained from a trematode and its use as a medicinal product

Publications (1)

Publication Number Publication Date
CH642682A5 true CH642682A5 (en) 1984-04-30

Family

ID=4196070

Family Applications (1)

Application Number Title Priority Date Filing Date
CH82579A CH642682A5 (en) 1979-01-26 1979-01-26 Peptide substance obtained from a trematode and its use as a medicinal product

Country Status (2)

Country Link
CH (1) CH642682A5 (zh)
FR (1) FR2447194A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582342B2 (en) 2003-07-18 2009-09-01 Degussa Ag Molding composition based on polyetheramides

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384992A (en) * 1981-01-27 1983-05-24 Andre Capron Novel peptide from cultures of Schistosoma mansoni, a process for producing it and pharmaceutical compositions containing the same
FR2601037B1 (fr) * 1986-07-03 1988-10-21 Pasteur Institut Peptide presentant des proprietes antigeniques isole de la proteine 28 kd de s. mansoni et son procede d'isolement, anticorps monoclonaux reconnaissant au moins un epitope dudit peptide et application de celui-ci dans l'induction de la synthese d'anticorps neutralisants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2149666A1 (de) * 1971-10-05 1973-04-12 Dr Senft Alfred W Proteinartiges material aus schistosoma und dieses enthaltendes diagnostisches praeparat

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582342B2 (en) 2003-07-18 2009-09-01 Degussa Ag Molding composition based on polyetheramides

Also Published As

Publication number Publication date
FR2447194B1 (zh) 1984-01-06
FR2447194A1 (fr) 1980-08-22

Similar Documents

Publication Publication Date Title
Toure-Balde et al. Plasmodium falciparum induces apoptosis in human mononuclear cells
CA2164646A1 (en) Anti-cd3 antibody-aminodextran conjugates for induction of t-cell activation and proliferation
EP0438332B1 (fr) Peptides dérivant de la glycoprotéine d'enveloppe de virus HIV, leurs applications à la détection d'une infection due à ces virus et à la vaccination contre le SIDA
EP1354599B1 (fr) Composition pharmaceutique ou alimentaire pour le traitement de pathologies liees a un rejet de greffe
FR2523976A1 (fr) Nouveau produit proteique, obtention et application comme medicament, en particulier immunoregulateur et antiallergique
EP0001197B1 (fr) Produits de couplage de la cytidine-diphosphocholine et de composés aminés, procédé d'obtention et application pharmaceutique et analytique
FR2489690A1 (fr) Procede d'obtention de la fraction ovomucoide et d'un extrait d'ovomucoide de l'oeuf de caille, produits ainsi obtenus et leur application a titre de medicament
JPH05501877A (ja) 抗ウィルス物質
CH642682A5 (en) Peptide substance obtained from a trematode and its use as a medicinal product
EP0605700B1 (fr) Composition pharmaceutique a base de flavopereirine et son utilisation dans un traitement contre le virus vih
Holgate et al. Primary and secondary effector cells in the pathogenesis of bronchial asthma
CA2142557C (fr) Facteur cytotoxique tel qu'associe a la sclerose en plaques, sa detection et sa quantification
Li et al. Cenicriviroc ameliorates the severity of graft-versus-host disease through inhibition of CCR5 in a rat model of liver transplantation
FR2543300A1 (fr) Reactif serologique
FR2657784A1 (fr) Facteur endogene cerebral, procede d'obtention et applications therapeutiques et diagnostiques.
AU719412B2 (en) Sugar-chain-recognizing antibodies and remedies for HIV infectious diseases
Gemmell et al. Apoptosis in Porphyromonas gingivalis–specific T‐cell lines
Parish et al. Mitogens and T-independent antigens stimulate T lymphocytes to secrete Ia antigens
FR3128229A1 (fr) Cellules t effectrices terminales, procédé pour leur production et leur isolement et leur utilisation thérapeutique
FR2620130A1 (fr) Nouveaux polysaccharides hydrosolubles, leur procede d'obtention, leur application a titre de medicaments et preparation les renfermant
EP0246967A1 (fr) Nouvelle lymphokine supressive de l'activation plaquettaire, son procédé d'isolement et de purification et médicaments la contenant
EP0314580B1 (fr) Application de groupes nitrophényles à la stimulation des capacités d'incorporation d'un médicament dans les cellules sensibles de l'hôte
Yeoh et al. Drug inhibition of anaphylactic histamine release from peritoneal cells of rats infected with Toxocara canis
FR2550094A1 (fr) Compositions de vaccins conditionnees pour la vaccination de sujets immunitairement non naifs contre un agent pathogene determine et contenant un haptene comportant lui-meme un site antigenique caracteristique dudit agent pathogene ou un oligomere de cet haptene
Stuart et al. The allergic macrophage of graft versus host disease

Legal Events

Date Code Title Description
PL Patent ceased